Review Article
Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data
Table 6
A summary of HRs for the overall and subgroup analyses of SALP and EFS of osteosarcoma patients.
| | Number of studies | Patients number | HR (95% CI) | Heterogeneity | Chi-squared | | value |
| Overall | 7 | 752 | 1.97 (1.61–2.42) | 7.65 | 21.6% | 0.265 | Age | | | | | | | Preadult and adult | 4 | 385 | 1.90 (1.45–2.48) | 5.33 | 43.7% | 0.149 | Preadult only | 3 | 367 | 2.07 (1.51–2.83) | 2.15 | 7.1% | 0.341 | Enneking stage | | | | | | | II | 3 | 321 | 1.88 (1.29–2.73) | 1.91 | 0% | 0.386 | II-III | 2 | 292 | 1.63 (1.19–2.23) | 1.32 | 24.3% | 0.250 | III | 2 | 139 | 2.77 (1.88–4.09) | 0.01 | 0% | 0.906 | Sample size | | | | | | | <100 | 5 | 306 | 2.28 (1.68–3.09) | 6.09 | 34.3% | 0.193 | >100 | 2 | 446 | 1.75 (1.33–2.31) | 0.02 | 0% | 0.89 | Geographic region | | | | | | | Asia | 2 | 112 | 2.34 (1.19–4.60) | 1.34 | 25.2% | 0.248 | Non-Asia | 5 | 640 | 1.94 (1.56–2.40) | 6.05 | 33.8% | 0.196 |
|
|
HR: Hazard ratio, EFS: event-free survival, and CI: confidence interval.
|